1 significantly exciting compound is LDN-27219. While most tTG inhibitors are designed to bind on the protein crosslinking Lively site, LDN-27219 alternatively binds towards the nucleotide binding pocket from the enzyme while it is actually in its closed-state conformation, and stabilizes that conformation to circumvent crosslinking activity.78 Schneider et al https://ldn-27219-preclinical-res81246.webdesign96.com/32068851/an-unbiased-view-of-ldn-27219-as-a-cancer-drug-candidate